NCT07646054
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers
Not Yet Recruiting
NAAges 60–80InterventionalPreventionScripps Translational Science InstituteInvestigator-initiated
~1,200 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Education
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Plasma pTau217 Concentration
Measured over Month 1, Month 6, Month 12
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Eric J Topol, MD · PRINCIPAL_INVESTIGATOR · Scripps Translational Research Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Current 23andMe Research participant with APOE4 positivity genetic variant
Age 60 to 80 at time of consent
Have access to an Android or Apple iPhone smartphone device and able to download study apps
Lives in the United States and able to send and receive US Mail
Able and willing to perform a self-administered saliva test at screening\*for organic outreach only.
Able and willing to perform a self-administered finger prick blood collection at three time points throughout the study.
Exclusion
Non-English speaking
Lives outside of the United States
Currently taking or planning on taking GLP-1 medications (Exenatide, Liraglutide, Albiglutide, Dulaglutide, Semaglutide or Tirzepatide) within the next 12 months
Established diagnosis of Mild Cognitive Impairment, Alzheimer's Disease or other Neurodegenerative Disease (Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, Multiple Sclerosis or Frontotemporal Dementia).
Current or past Oura Ring user (any Oura Ring use in the last 12 months)
What this trial measures
- Plasma pTau217 ConcentrationMonth 1, Month 6, Month 12
Plasma phosphorylated tau 217 (pTau217) concentration will be measured from self-collected dried blood spot samples at three timepoints across the 12-month active monitoring period. Both absolute concentration at each time point and change from baseline will be assessed.